Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sintilimab maintenance after first-line GP chemotherapy in advanced squamous non-small cell lung cancer
ChiCTR1900026448Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Pulmonary squamous cell carcinoma, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: progression-free survival. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR1900026448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026448.